This week we will be reading about the neurological disorders and musc This week we will be reading about the neurological disorders and musculoskeleton system disorders; along with the drugs used to treat those disorders. We will specifically focus on Parkinson Disease, Alzheimer disease, Epilepsy, rheumatoid arthritis, and gout. The case assignment for Week 6 is: decision_trees/week_10/index.html
Paper For Above instruction Introduction Neurological and musculoskeletal disorders pose significant challenges worldwide, affecting millions of individuals and impairing their quality of life. Understanding these disorders, their pathophysiology, and the pharmacological treatments available is crucial for advancing clinical practice and improving patient outcomes. This paper provides an in-depth exploration of Parkinson’s Disease, Alzheimer’s Disease, Epilepsy, Rheumatoid Arthritis, and Gout, focusing on their clinical features, underlying mechanisms, and pharmacotherapy options. Neurological Disorders **Parkinson’s Disease** is a progressive neurodegenerative disorder characterized primarily by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the basal ganglia (Kalia & Lang, 2015). Pharmacological management commonly includes levodopa, which is converted to dopamine in the brain, along with dopamine agonists, MAO-B inhibitors, and COMT inhibitors to enhance dopaminergic activity (Olanow & Schapira, 2013). Despite symptomatic relief, no cure exists, and ongoing research aims to develop neuroprotective therapies. **Alzheimer’s Disease** is the most common form of dementia, characterized by progressive cognitive decline, memory impairment, and behavioral changes. The underlying pathophysiology involves amyloid-beta plaque accumulation, neurofibrillary tangles, and neuronal loss (Jack et al., 2013). Treatment strategies include cholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine), which aim to improve cognitive function and delay disease progression (Birks, 2006). Recent advances focus on disease-modifying treatments targeting amyloid and tau proteins. **Epilepsy** is a neurological disorder marked by recurrent seizures caused by abnormal electrical